Agios Pharmaceuticals Investor Relations Material
Latest events
Q2 2025
Agios Pharmaceuticals
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Agios Pharmaceuticals Inc
Access all reports
Agios Pharmaceuticals Inc. is a biopharmaceutical company focused on discovering and developing therapies for genetically defined diseases. The company leverages its expertise in cellular metabolism and genetic pathways to create treatments for rare and severe conditions, including metabolic and hematologic disorders. The company is headquartered in Cambridge, Massachusetts, and its shares are listed on the NASDAQ.
Key slides for Agios Pharmaceuticals Inc
Q4 2024
Agios Pharmaceuticals Inc
Q1 2025
Agios Pharmaceuticals Inc
Latest articles
)
Verisure: Security Leader Ready for a Comeback IPO
Verisure, Europe's leading monitored alarm provider, is preparing a comeback IPO in 2025 that could be one of the year's most significant listings.
16 Sep 2025
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
Ticker symbol
AGIO
Country
🇺🇸 United States